Re-Envisioning Talent Management for the 4th Industrial Revolution: A Systems and Design Thinking Intervention

This dissertation examines the application of interactive planning as an intervention for the purpose of exploring its effectiveness with diverse, cross-organizational stakeholders when considering an issue that transcends individual organizations. The case study offers a practitioner method and approach using systems and design thinking to re-envision talent management in the 4th Industrial Revolution. The first two phases of a three-phase model, entitled Consider, Research, Explore, Associate, Theorize, and Empathize, (C.R.E.A.T.E.) contains aspects of systems and design thinking, and are addressed in this study. Data were gathered from direct observation and facilitation of two stakeholder sessions. The first, in Blue Bell, Pennsylvania, included participants employed in a variety of roles from across industries and companies in the Greater Philadelphia area. The second, in Austin, Texas, included external human capital consultants across the United States and Canada who were all partner-members of Career Partners International (CPI). Results indicated that stakeholders representing different organizations, roles and boundaries can enter into generative space regarding a common issue. Results also show designs with emergent themes that have the potential to influence the creation of an effective talent management system, and the C.R.E.A.T.E. model can be applied to accelerate the pace of innovation and creative solution seeking with regard to issues of complexity. Reflections on the facilitation process and a timeline practitioners can use with internal and external clients are provided along with suggestions for future research into this highly collaborative and interactive process

Building a New Frame of Reference: An Adult Transformational Approach

Coaching is a process by which a coach engages with a client to help realize personal or professional development goals. A successful coaching process is holistic; taking into account the individual’s expressed desires, their observable behaviors and relationships, all in the context of their needs. Reflecting on how theory informs a coaching practice is important for the practitioner to move beyond intuition and permit theory to influence interventions while also allowing for the observable data to be grounded in a framework that further informs their practice. This paper presents the case study of an OCEC Coaching Practicum Engagement and subsequent work done after the original contract expired. In addition, an exploration of the ethical values ascribed to by the Coach, the theory that informed the methods used during the coaching engagement, and how the data contributed to the Coach’s theoretical view and methods used will be included. In consideration for the importance of self-awareness during the coaching process this paper will be written in the first person, from the perspective of the Coach, and integrate personal background and reflection throughout the stages of the coaching engagement

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience

Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined safety profile in patients with various CD20-expressing lymphoid malignancies, including indolent and aggressive forms of B-cell non-Hodgkin lymphoma. Since its first approval 20 years ago, intravenously administered rituximab has revolutionized the treatment of B-cell malignancies and has become a standard component of care for follicular lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and mantle cell lymphoma. For all of these diseases, clinical trials have demonstrated that rituximab not only prolongs the time to disease progression but also extends overall survival. Efficacy benefits have also been shown in patients with marginal zone lymphoma and in more aggressive diseases such as Burkitt lymphoma. Although the proven clinical efficacy and success of rituximab has led to the development of other anti-CD20 monoclonal antibodies in recent years (e.g., obinutuzumab, ofatumumab, veltuzumab, and ocrelizumab), rituximab is likely to maintain a position within the therapeutic armamentarium because it is well established with a long history of successful clinical use. Furthermore, a subcutaneous formulation of the drug has been approved both in the EU and in the USA for the treatment of B-cell malignancies. Using the wealth of data published on rituximab during the last two decades, we review the preclinical development of rituximab and the clinical experience gained in the treatment of hematologic B-cell malignancies, with a focus on the well-established intravenous route of administration. This article is a companion paper to A. Davies, et al., which is also published in this issue